Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA
about
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptorsAdenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson diseaseBasal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.Non-dopaminergic drug treatment of Parkinson's disease.Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's diseaseA(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseConstant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Dyskinesias in Parkinson's disease: views from positron emission tomography studies.Molecular imaging of levodopa-induced dyskinesias.Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.PBF509, an Adenosine A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
P2860
Q27021464-4F42B77A-2AC9-4E93-9995-6032452C9D9AQ28204434-5204C0C4-AAC0-4F34-8D07-2291CD86E510Q29346490-5D2782C8-7A50-4C0F-9D1D-E78E938CB925Q34165820-8680CDA5-EDB1-4DC6-BFEE-8919BF5ABE8AQ34240947-D86FD406-8416-4E23-99D3-75307ACE090AQ34325365-49B88DE3-3B74-446B-8592-33E5D8D5DD51Q34419833-BEA42683-CC70-4070-AA46-2BC2A09F6C9DQ36057652-A1FDE7C4-D93F-482C-B761-4DC8208CC329Q37016310-E4D38FF9-BE79-4E60-B279-3D09A2C7FC2AQ37712460-535241F3-2A23-487F-AD5F-76E73A7A2BA4Q37924629-FEA61BB9-A6F8-4A38-B966-8C4FFF45ECAFQ38182651-1C55EA2B-7325-4F40-AAE5-E89E5BF3BB11Q38355582-7040CAFF-C425-49BD-AFD2-42D6F078E2C2Q41584434-78A233E7-D7CB-4E50-9907-C926553654FEQ42747563-824F61FD-5C46-476A-BA2C-62168D4346A9Q43959920-D8371D92-BCE4-48C8-82AC-355BF1AC3DE9Q44165230-83E5BCE2-B708-47AE-99F4-0EE19B742F22Q44175279-45269609-F71A-40BC-92B1-9AC51FB32687Q44243014-533032E2-E349-4536-B226-F2F7B82DE08AQ45711922-EAF4623C-F3E9-472B-9AF2-841BEA7499C5Q58587583-EAF85F8B-3673-4FA6-9F9A-69EAD9DC4CAB
P2860
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Alterations in preproenkephali ...... hronically treated with L-DOPA
@ast
Alterations in preproenkephali ...... hronically treated with L-DOPA
@en
Alterations in preproenkephali ...... hronically treated with L-DOPA
@nl
type
label
Alterations in preproenkephali ...... hronically treated with L-DOPA
@ast
Alterations in preproenkephali ...... hronically treated with L-DOPA
@en
Alterations in preproenkephali ...... hronically treated with L-DOPA
@nl
prefLabel
Alterations in preproenkephali ...... hronically treated with L-DOPA
@ast
Alterations in preproenkephali ...... hronically treated with L-DOPA
@en
Alterations in preproenkephali ...... hronically treated with L-DOPA
@nl
P2093
P2860
P1476
Alterations in preproenkephali ...... hronically treated with L-DOPA
@en
P2093
G M MacKenzie
R K Pearce
P2860
P304
P356
10.1046/J.1460-9568.2000.00988.X
P407
P577
2000-03-01T00:00:00Z